Is rasagiline necessary for long-term use? Dosage cycle and the need for continued treatment

Rasagiline is a monoamine oxidase B inhibitor (MAO-B inhibitor). It is mainly used for the treatment of Parkinson's disease. It is especially suitable for early monotherapy or combination with levodopa and other drugs to relieve the symptoms of "switch phenomenon". As one of the long-term management drugs for Parkinson's disease, rasagiline's mechanism of action is to improve motor symptoms by reducing the degradation of dopamine in the brain and prolonging its action time. Therefore, in most cases, rasagiline requires long-term continuous use to maintain a stable therapeutic effect.

Parkinson's disease is a chronic, progressive neurological disease. As the course of the disease increases, the patient's symptoms will gradually worsen. At different stages of the disease, rasagiline can be flexibly used as a single agent or in combination therapy, and its long-term application can help delay the progression of the disease and improve patients' daily activities. Multiple studies have shown that rasagiline not only helps improve core symptoms such as tremor, bradykinesia, and myotonia, but may also have a certain neuroprotective effect. Because of this, doctors often recommend that patients continue to take the medication on a long-term treatment plan to obtain sustained, stable benefits.

However, whether rasagiline needs to be used for life needs to be judged based on individualized conditions. If the patient's symptoms are well controlled when using rasagiline monotherapy in the early stage, the original dose can usually be maintained for long-term use. When the disease progresses to the mid-to-late stage, drug efficacy fluctuations or motor complications occur, the treatment plan may need to be adjusted and used in combination with other anti-Parkinson drugs. During the entire treatment process, patients should have regular follow-up visits, and neurologists will evaluate the efficacy and side effects to ensure the rationality and safety of the medication regimen.

It is worth noting that long-term use of rasagiline is usually well tolerated and is not likely to cause serious adverse reactions and will not lead to drug dependence or obvious withdrawal symptoms. However, stopping the drug without authorization may lead to a sudden worsening of symptoms. Therefore, if patients need to adjust or stop taking rasagiline, they should do so gradually under the guidance of a doctor to avoid affecting the treatment effect. Overall, for most patients with Parkinson's disease, rasagiline is a stable treatment regimen worthy of long-term use, and its continued use has positive significance in delaying the disease and improving quality of life.

Reference materials:https://www.azilect.com/